Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388464 | 1.00 | LDHA (0.57) | LDHACA2KDM4EATMALOX15 | |
| SCHEMBL10412987 | 0.86 | FOS (0.62) | ATMALOX15ALOX12ALDH1A1TSHR | |
| SCHEMBL8076708 | 0.83 | LDHA (0.60) | LDHACA2KDM4EATMALOX15 | |
| SCHEMBL4247499 | 0.83 | LDHA (0.60) | LDHACA2KDM4EATMALOX15 | |
| SCHEMBL5792794 | 0.81 | LDHA (0.58) | LDHACA2KDM4EATMALOX15 | |
| SCHEMBL9394901 | 0.81 | HTR2A (0.49) | CA2CYP19A1AOC3CA12CA1 | |
| SCHEMBL2564908 | 0.79 | LDHA (0.59) | LDHACA2KDM4EATMALOX15 | |
| SCHEMBL31545634 | 0.79 | LDHA (0.59) | LDHACA2KDM4EATMALOX15 | |
| SCHEMBL31545527 | 0.79 | LDHA (0.59) | LDHACA2KDM4EATMALOX15 | |
| SCHEMBL3371646 | 0.79 | LDHA (0.59) | LDHACA2KDM4EATMALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1078002-B1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LAB (US) | 2008-05-21 | — | — | EP | claimed |
| US-20050124548-A1 | Peptide antiangiogenic drugs | HENKIN JACK (US) | 2005-06-09 | — | — | US | claimed |
| US-6753408-B1 | DRUGS USED FOR THERAPY | ABBVIE INC. | 2004-06-22 | — | — | US | claimed |
| US-6716963-B1 | OLIGOPEPTIDES | ABBOTT LABORATORIES | 2004-04-06 | — | — | US | claimed |
| EP-1232183-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2002-08-21 | — | — | EP | claimed |
| WO-2001038347-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| EP-1078002-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999061476-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | claimed |
| EP-1078002-B1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LAB (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20050124548-A1 | Peptide antiangiogenic drugs | HENKIN JACK (US) | 2005-06-09 | — | — | US | disclosed |
| US-6774211-B1 | Peptide antiangiogenic drugs | ABBOTT LABORATORIES | 2004-08-10 | — | — | US | disclosed |
| US-6753408-B1 | DRUGS USED FOR THERAPY | ABBVIE INC. | 2004-06-22 | — | — | US | disclosed |
| US-6716963-B1 | OLIGOPEPTIDES | ABBOTT LABORATORIES | 2004-04-06 | — | — | US | disclosed |
| EP-1232183-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001038347-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1078002-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999061476-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124548-A1 | Peptide antiangiogenic drugs | VEGFA, NPPA, FLT1 | LDHA 1454/4885CA2 2504/4885KDM4E 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.